Is Cytosorbents Corporation (CTSO) a Buy, Sell, or Hold?
NASDAQ : CTSO
Cytosorbents Corporation — News
$0.3609 USD
$0.01 (3.08%)
- Volume
- 87.72K
- Average Volume
- 160.04K
- Market Capitalization
- $22.68M
- P/E Ratio
- -1.94
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.22
- Year Low
- $0.35
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.09
| Source | Headline |
|---|---|
|
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights
PRINCETON, N.J., July 20, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2026 financial results and recent business highlights after the market close on Thursday, August 6, 2026. prnewswire.com - 2026-07-20 07:00:00 |
|
CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026
PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Life Sciences Forum hosted by VirtualInvestorConferences.com on Wednesday, June 24, 2026 and provide an overview and update on the Company. Following the presentation, Zacks Analyst Mr. Thomas Kerr will host a brief Q&A session with Dr. Chan and Mr. Peter Mariani, Chief Financial Officer. globenewswire.com - 2026-06-18 08:46:00 |
|
Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript
Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-05-13 19:30:49 |
|
CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
PRINCETON, N.J., May 13, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2026, recent business highlights, and provides a regulatory update. prnewswire.com - 2026-05-13 16:00:00 |
